FOR IMMEDIATE RELEASE:

Jellyfish Protein Shows Powerful Neuroprotectant Activity

Chicago, Illinois (April 8, 2006)

Quincy Bioscience (Madison, WI) announces that their proprietary technology consisting of the jellyfish protein aequorin has displayed potent neuroprotectant activity in their laboratory studies. Quincy Bioscience has been researching the jellyfish protein for the past ten years and has recently demonstrated a significant ability to keep brain cells alive longer in controlled tests when an ischemic event is administered. Laboratory tests show a 28-45% improvement in cellular protection from death in their rodent models studied.

The specific area of the brain studied was the hippocampus, a region that is responsible for short term memory formation. "Without a properly functioning hippocampus, if you looked away from me right now and turned back, you would have to reintroduce yourself to me, having forgotten that we just met," commented James Moyer, Jr. Ph.D. of the University of Wisconsin at Milwaukee (UWM). Dr. Moyer is Quincy Bioscience's primary investigator within the Neurosciences Laboratory at UWM. "Investigating the hippocampus is crucial to understanding the molecules impact on the largest neurodegenerative disease, Alzheimer's."

Quincy Bioscience will be detailing their discovery and its implications on healthcare at the Biotechnology Industry Organization (BIO) 2006 meeting on Tuesday, April 11th at 2:30 in the afternoon. The presentation will be made in the state of Wisconsin's Discovery Theater located at booth #2570.

Quincy Bioscience sponsors research conducted at the University of Wisconsin at Milwaukee to develop aequorin-based technologies for the treatment of neurological conditions such as Alzheimer's, Parkinson's, stroke, Amyotrophic Lateral Sclerosis (ALS) and Huntington's Disease (HD). In each of these disorders there is a known depletion in neuroprotective calcium-binding proteins that is highly correlated with disease progression and severity. Quincy Bioscience's molecule is intended to essentially replace those lost proteins.

"We are very excited to be moving this technology forward. There are many people suffering from these diseases," commented Mark Underwood, President of Quincy Bioscience. "Both academic labs and drug companies are searching for a molecule that can attenuate neuronal loss from calcium-mediated toxicity. We have one. Now it is time to focus on selecting the right partners that can take this to the next level."

A certain species of jellyfish contains the protein aequorin which has the unique property of binding calcium ions within the nervous system of the jellyfish. Humans also need this type of protein to properly protect cells. One of the detriments of the aging process is that humans lose a significant amount of their own cell-protecting proteins. Aequorin is a very similar type of protein with no toxicity issues. Clinical trials are planned to investigate aequorin's impact in patients. This technology would not be possible without some significant advances in biotechnology manufacturing. Jellyfish protein used to be very difficult to obtain and expensive. Two tons of jellyfish would only yield 125mg of aequorin. Now with safe production techniques the protein is more economically feasible to be utilized as a therapeutic.

"The response to the technology has been very positive from pharmaceutical companies. Since aequorin targets a very important mechanism of action it has the potential for the treatment of several neurodegenerative conditions." Underwood also added. Interest in Quincy Bioscience's technology has been growing as potential licensing partners are looking at applications of this technology towards everything from acute treatments for post-stroke trauma to longer term anti-aging research.

"Having strong science is the key to providing a quality product to our consumer base," added Mike Beaman, Mr. Underwood's partner in Quincy Bioscience. "It is exciting that we can have the opportunity to touch the health of so many others. This protein is rather amazing."

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the disease of aging. The company's therapeutic products focus on restoring calcium balance related to neurodegenerative disorders and the destructive age-related mechanisms triggered by calcium. Quincy Bioscience is set apart by its cutting-edge health applications of the jellyfish protein aequorin. Aequorin has proven neuroprotective activity and is being developed for pharmaceutical product applications.

For more information, contact Mark Underwood, President at munderwood@quincybioscience.com or 414-303-0814.